November 2023
Guest editor: Lotte Steuten | Deputy Chief Executive
The recent UK proposals aimed at incentivising the development of new antibiotics are significant. They are novel, the first of their kind, and will send signals to other countries regarding the importance of such a scheme and how it can be actioned. However, our research has highlighted changes that will be needed if the scheme is to successfully meet its aims.
Investors play a pivotal role in the development of antibiotics, and our interviews with nine key stakeholders revealed valuable insights. While all investors recognised the significance of the UK proposals, concerns were raised about the scheme's effectiveness as a pull incentive.
Some proposed criteria, e.g. requiring randomised controlled trial evidence, are particularly challenging for antibiotics research. Further, considering an extended initial contract length for the scheme could encourage innovation without delaying progress.
Investors highlighted the need for the scheme to be more predictable. The existence of multiple value bands, a changing scoring system, and uncertainty over contract length limit their current appetite to invest. Clear signposting and transparent collaboration in reviewing criteria over time would address these concerns.
Furthermore, the international dimension is critical. While the upper payment bands are judged adequate for England, global collaboration, especially with the EU and the USA, is essential to create a sufficient minimum pull incentive globally. Coordination across schemes is therefore necessary to ensure a cohesive effort against antibiotic resistance.
The proposed scheme shows real promise but requires strategic enhancements. Revisiting evidence requirements, ensuring global alignment, revising payment amounts, and clarifying the scheme's long-term commitment will strengthen its impact. These adjustments, along with international collaboration, will not only support the UK's efforts but serve as a blueprint for effective pull incentives worldwide.
NEW FROM OHE
OHE’s latest report explores the proposed pull incentive for antibiotic development in the UK. Nine in-depth interviews with financial investors and biopharma executives reveal their optimism but highlight critical areas for improvement.
Discover why investors consider a transparent, collaborative process, extended contract length, and global harmonisation essential for an effective pull incentive. The report also highlights the shaping of policies that incentivise innovation.
In this report, we look into the transformative power of innovation and the barriers delaying its adoption. The nine obstacles include technology barriers, regulatory and policy barriers, and funding challenges. With healthcare systems globally facing post-pandemic challenges, collaboration is vital to overcoming barriers and propelling innovation towards efficiency.
Multistakeholder partnerships, like the ATTC network and Fast-Track Cities London, break down silos, boost knowledge exchange, and drive policy influence.
Our report analyses the 'volume-delinked model' subscription approach proposed to overcome market obstacles hindering new antibiotics, to inform NHS England's public consultation.
We share insights on the unique dummy product exercise, revealing critical criteria for antibiotic valuation.
We discuss the scoring system and value bands for eligible antimicrobials, with key takeaways showing the challenges and opportunities in this crucial field.
The Inflation Reduction Act (IRA) brings unprecedented changes, including the Medicare Drug Price Negotiation Program.
With the U.S. government gaining authority to set drug prices, in this insight, we reflect on the potential impacts on drug innovation, revenue, and global R&D, as discussed at key international conferences.
Uncertainties still surround price-setting methods and the broader implications for the pharmaceutical industry. Find out the details of the IRA's influence on drug pipelines, patient access, and global markets.
Read why a new system is essential in addressing antimicrobial resistance (AMR) and how the UK proposes a pull incentive scheme for novel antibiotics.
This insight evaluate the scoring system's effectiveness and summarises the views of investors to antibiotic development.
We look into proposed actions to strengthen the scheme, ensuring it aligns with international efforts. Read our AMR consultation response to comprehensively understand the challenges and opportunities in combating AMR.
Antibiotics, pivotal in modern healthcare, hold value beyond conventional measure. The STEDI framework's five key elements shaping the broader value of antibiotics - Spectrum, Transmission, Enablement, Diversity, and Insurance.
The three-phase roadmap addresses challenges, from clarifying concepts to establishing standards for a comprehensive quantitative assessment. This innovation requires collective interdisciplinary action for impactful change.
Read the report for a deeper understanding of how collective action and interdisciplinary collaboration can revolutionise the future of antibiotic innovation.
EVENTS
07 December 2023 | Panel
Emphasising health awareness and preventive measures from an early age is important to fostering longer, healthier lives and safeguarding countries' healthcare budgets.
Join Lotte Steuten during the Transforming Health System to Achieving Healthier Aging at All Ages panel at the High-level Forum on the Silver Economy 2023. This insightful session will explore the necessary investments in innovation to enhance prediction, prevention, treatment, and care. Taking place from 8:40 at The Paley Centre for Media in New York.
7 December 2023 | Webinar
Join our expert panel as they offer a range of perspectives on the breadth of challenges, and solutions, associated with enhancing uptake next generation sequence testing.
This 90-minute webinar will build on the recommendations from the recently published report by OHE and Takeda: 'The Case for Expanding Uptake of Next-Generation Sequencing for Lung Cancer in Europe'.
31 January | Webinar
Our experts will reflect on the highlights and lowlights of the past year. We will be spotlighting which have had the biggest impact in 2023, and discussing which emerging issues we have identified for 2024. Agenda and panel information to follow.